Moderna on Monday lowered its 2025 sales guidance by roughly $1 billion due to a few potential headwinds later this year, as the biotech company continues to cut costs and expand its portfolio.

tag:reuters.com,2021:binary_RC2LCR9J0GV3-BASEIMAGE

Reuters

United Kingdom

Moderna cuts 2025 sales forecast by $1 bln on weak vaccine demand, shares fall

Shares of Moderna tumbled Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year

Ad Fontes Media

All Sides

Media Bias/Fact Check

The Independent

Evgeny Lebedev

London

Greater London

England

Moderna surprises the Street by predicting a bigger-than-expected sales drop

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines, sending its shares down more than 18% in premarket trading.

The Woodbridge Company

abc News

The Walt Disney Company

United States

Moderna now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of which will come in the second half of the year.

CNBC

Roberts family

Moderna stock plunges 18% after company lowers 2025 sales forecast by $1 billion

Moderna Inc. entered the new year on the heels of a worsening stock performance in 2024. The Cambridge drugmaker’s stock dropped even further after lowering its expected revenue range for 2025 during the J.P. Morgan Healthcare Conference.

The Business Journals

Advance Publications

Moderna stock drops on lower 2025 guidance, more cost cuts

Cost-cutting measures announced include scaling back research and development spending by 20 percent.

Newsweek

IBT Media

Moderna shares plunge after predicting steep 2025 sales decline

Shares of Moderna tumbled in early trading Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year. Moderna said it expects 2025 revenue to range between $1.5 billion and $2.5 billion after hitting as much as $3.

Rocky Mountain Outlook

Glacier Media

Moderna cut its 2025 sales forecast by $1 billion today, hurt by a slow adoption of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines, sending its shares down more than 18% in premarket trading.

Star Advertiser

Torstar

David Black

Honolulu

Honolulu County

Hawaii

Moderna cuts 2025 sales forecast by $1B on weak vaccine demand | Honolulu Star-Advertiser

Shares of Moderna tumbled in early trading Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year.Moderna said it expects 2025 revenue to range between $1.5 billion and $2.5 billion after hitting as much as $3.1 billion last year.Analysts expect, on average, $2.92 billion in revenue for 2025, according to FactSet.The company also said it was speeding up and expanding a cost-cutting plan. It expects to cut cas…

WPLG

Howard Buffett

Miami

Miami-Dade County

Florida

Faced with low demand, the American pharmaceutical company is revising its forecasts downwards for 2025....

Face à une faible demande, l'entreprise pharmaceutique américaine revoit ses prévisions à la baisse pour 2025. ...

Moderna s'effondre en Bourse : l'action perd plus de 20 %

La Libre

Brussels

Belgium

Moderna collapses on the stock market: the stock loses more than 20%

Moderna

Business

US Economy

Economy

Stock Markets

Vaccines

Coronavirus

MarketWatch

Novinky.cz

Seeking Alpha

Zero Hedge

U.S. News

ZF.ro

The Motley Fool

BizToc

Upstract

Jingletree

IBTimes UK

Investor's Business Daily

Expansión

manager magazin

El CEO

Stockxpo - A professional network of traders, investors and analysts

Consenso del Mercado

Portfolio.hu

RocketNews

Sky News: The Latest News from the World

thefinancialanalyst.net

elblog.pl

franktrades.com

Verve times

bolsamania.com

Endpoints News

Phil's Stock World

sherwood.news

Busines and Oil News

2 News KTVN

pharmaceutical-technology.com

biopharmadive.com

Wall Street Pit

SHTF Plan

financialbuzz.com

healtheconomics.com

Moderna stock plunges 18% after company lowers 2025 sales forecast by $1 billion

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics